Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Rhea-AI Summary

Blueprint Medicines (NASDAQ: BPMC) has announced it will host a live conference call and webcast to report its fourth quarter and full year 2024 financial results on Thursday, February 13, 2025, at 8:00 a.m. ET. The company will also provide a corporate update during the event.

Investors can access the conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with conference ID 349846. A webcast will be available on the company's investor relations website, with an archived version accessible for 30 days after the call.

News Market Reaction

-2.67%

1 alert

-2.67% News Effect

On the day this news was published, BPMC declined 2.67%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 13, 2025, to report its fourth quarter and full year 2024 financial results and provide a corporate update.

To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 349846. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT^®/AYVAKYT^® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit www.BlueprintMedicines.com and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday-february-13-2025-302368185.html

SOURCE Blueprint Medicines Corporation

FAQ

When will Blueprint Medicines (BPMC) report Q4 and full year 2024 earnings?

Blueprint Medicines will report its Q4 and full year 2024 financial results on Thursday, February 13, 2025, at 8:00 a.m. ET.

How can investors access BPMC's Q4 2024 earnings call?

Investors can access the call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with conference ID 349846, or via webcast on Blueprint Medicines' investor relations website.

How long will BPMC's Q4 2024 earnings webcast be available?

The archived webcast will be available on Blueprint Medicines' website for 30 days following the call.

What will be discussed in BPMC's February 13, 2025 conference call?

The conference call will cover Blueprint Medicines' fourth quarter and full year 2024 financial results and provide a corporate update.